Getting the Most from Real-World Data Analytics for Payers

blue digital binary data on computer screen. Close-up shallow DOF

Real-world evidence (RWE) and real-world data (RWD) are increasingly used in decision-making across the drug development and market access timeline. Payer organizations, however, have yet to reap the full benefits of RWD and RWE analytics. In a new Pharmacy Times article, Matthew Marshal examines how payers can implement RWD and RWE analytics moving forward.

According to Matthew Marshall, “Progressive payer organizations have already started to leverage data analytics to improve processes and save on costs. Analytics can allow payers to gain a better understanding of the needs of their member populations and the barriers they face in accessing care, which can help them design better programs and data-backed initiatives to meet these needs. Among payers who are currently using analytics, a few of the most common use cases are program design and evaluation, service utilization benchmarking, and benefit design.”

To read more, click here.

(Source: Pharmacy Times, September 21^st, 2022)